Amgen (AMGN) reported $8.15 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 9.4%. EPS of $4.90 for the same period compares to $3.96 a year ago.

The reported revenue represents a surprise of +2.47% over the Zacks Consensus Estimate of $7.95 billion. With the consensus EPS estimate being $4.16, the EPS surprise was +17.79%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Amgen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Product Sales- Neulasta- ROW: $20 million versus the seven-analyst average estimate of $26.10 million. The reported number represents a year-over-year change of -35.5%.
• Product Sales- Neulasta- U.S. $109 million versus the seven-analyst average estimate of $67.86 million. The reported number represents a year-over-year change of +25.3%.
• Product Sales- Otezla- ROW: $94 million compared to the $103.34 million average estimate based on six analysts. The reported number represents a change of -6.9% year over year.
• Product Sales- Otezla- U.S. $343 million compared to the $299.70 million average estimate based on six analysts. The reported number represents a change of +17.1% year over year.
• Product Sales- BLINCYTO- Total: $370 million compared to the $337.78 million average estimate based on 10 analysts. The reported number represents a change of +51.6% year over year.
• Product Sales- Repatha- Total: $656 million versus the 10-analyst average estimate of $615.59 million. The reported number represents a year-over-year change of +26.9%.
• Product Sales- KYPROLIS- Total: $324 million versus the 10-analyst average estimate of $381.49 million. The reported number represents a year-over-year change of -13.8%.
• Product Sales- Vectibix- Total: $267 million versus the 10-analyst average estimate of $250.50 million. The reported number represents a year-over-year change of +8.1%.
• Product Sales- Enbrel- Total: $510 million versus $502.53 million estimated by 10 analysts on average. Compared to the year-ago quarter, this number represents a -10.1% change.
• Revenue- Other revenues: $276 million versus the 10-analyst average estimate of $347.10 million. The reported number represents a year-over-year change of -16.1%.
• Product Sales- Neulasta- Total: $129 million compared to the $93.87 million average estimate based on 10 analysts. The reported number represents a change of +9.3% year over year.
• Revenue- Product sales: $7.87 billion compared to the $7.59 billion average estimate based on 10 analysts. The reported number represents a change of +10.6% year over year.

View all Key Company Metrics for Amgen here>>>

Shares of Amgen have returned -4.8% over the past month versus the Zacks S&P 500 composite's -0.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Amgen Inc. (AMGN) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research